Maud Salmona

Maud Salmona

Auto-generated profile, based on publicly available information

Maud Salmona

Hôpital Saint-Louis

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in International Journal of Hygiene and Environmental Health
Verified
Journal Article
Closed access
OPOlivier Peyrony
Olivier Peyrony
SESami Ellouze
Sami Ellouze
JFJean-Paul Fontaine
Jean-Paul Fontaine
MCMicheline Thegat-Le Cam
Micheline Thegat-Le Cam
MSMaud Salmona
Maud Salmona
MTM.T. Tremorin
M.T. Tremorin

1 October 2015 in Vaccine
Verified
Journal Article
Closed access
MSMaud Salmona
Maud Salmona
SGSandrine Gazaignes
Sandrine Gazaignes
SMSeverine Mercier-Delarue
Severine Mercier-Delarue
FGFabienne Garnier
Fabienne Garnier
JKJehanara Korimbocus
Jehanara Korimbocus
FSFrançois Simon
François Simon

Verified
Journal Article
Open access
PDF file
NNNicole NOURIE
Nicole NOURIE
CBCéline Boueri
Céline Boueri
HMHoang Tran Minh
Hoang Tran Minh
GDGillian Divard
Gillian Divard
CLCarmen Lefaucheur
Carmen Lefaucheur
KLKevin Louis
Kevin Louis
BK polyomavirus (BKPyV) infection of the kidney graft remains a major clinical issue in the field of organ transplantation. Risk factors for BKPyV-associated nephropathy (BKPyVAN) and molecular tools for determining viral DNA loads are now better defined. BKPyV DNAemia in plasma, in particular, plays a central role in diagnosing active infection and managing treatment decisions. However, significant gaps remain in the development of reliable biomarkers that can anticipate BKPyV viremia and predict disease outcomes. Biomarkers under active investigation include urine-based viral load assays, viral antigen detection, and immune responses against BKPyV, which may offer more precise methods for monitoring disease progression. In addition, treatment of BKPyVAN is currently based on immunosuppression minimization, while the role of adjunctive therapies remains an area of active research, highlighting the need for more personalized treatment regimens. Ongoing clinical trials are also exploring the efficacy of T-cell-based immunotherapies. The clinical management of BKPyV infection, based on proactive virological monitoring, immune response assessment, integrated histopathology, and timely immunosuppression reduction, is likely to reduce the burden of disease and improve outcomes in kidney transplantation.

26 April 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
GFGregoire Martin de Frémont
Gregoire Martin de Frémont
AVAnthony Vanjak
Anthony Vanjak
ZSZineb Sbihi
Zineb Sbihi
SKSilene Knapp
Silene Knapp
MGMargaux Garzaro
Margaux Garzaro
DBDavid Boutboul
David Boutboul
Kaposi sarcoma–associated herpesvirus (KSHV)/human herpesvirus 8–associated multicentric Castleman disease (MCD) is a polyclonal B-cell lymphoproliferative disorder that mainly occurs in immunocompromised hosts. The diagnosis relies on lymph node biopsy demonstrating KSHV-infected cells located in the mantle zone with a marked interfollicular plasma cell infiltration. Infected cells are large cells positive for immunoglobulin M (IgM), λ light chain, and CD38, described initially as infected plasmablasts. We show that IgM+λ+CD38high cells were also detectable in the peripheral blood of 14 out of 18 (78%) patients with active KSHV-MCD and absent in 40 controls. Using immunofluorescence and flow–fluorescence in situ hybridization, we demonstrate that these cells are KSHV infected and express both latent and lytic KSHV transcripts. These KSHV-infected viroblasts (KIVs) harbor a distinct phenotype compared with conventional plasmablasts. We also identified several putative mechanisms of immune escape used by KSHV, because KIVs displayed an overall decrease of costimulatory molecules, with a remarkable lack of CD40 expression and are interleukin-10–producing cells. The identification of this specific and easily accessible KSHV+ circulating population brings new elements to the understanding of KSHV-MCD but also raises new questions that need to be clarified.

1 December 2021 in Journal of Infection
Verified
Journal Article
Closed access
GPGauthier Péan de Ponfilly
Gauthier Péan de Ponfilly
ACAnthony CHAUVIN
Anthony CHAUVIN
MSMaud Salmona
Maud Salmona
HBHanaa Benmansour
Hanaa Benmansour
BBBéatrice Bercot
Béatrice Bercot
HJHervé Jacquier
Hervé Jacquier

16 December 2023 in Journal of Medical Virology
Verified
Journal Article
Open access
LFLinda Feghoul
Linda Feghoul
ACAmandine Caillault
Amandine Caillault
OPOlivier Peyrony
Olivier Peyrony
MSMaud Salmona
Maud Salmona
MNMarie‐Laure Nere
Marie‐Laure Nere
JLJérôme LeGoff
Jérôme LeGoff
Accurate prediction of COVID‐19 severity remains a challenge. Torque teno virus (TTV), recognized as a surrogate marker of functional immunity in solid organ transplant recipients, holds the potential for assessing infection outcomes. We investigated whether quantifying TTV in nasopharyngeal samples upon emergency department (ED) admission could serve as an early predictor of COVID‐19 severity. Retrospective single‐center study in the ED of Saint‐Louis Hospital in Paris, France. TTV DNA was quantified in nasopharyngeal swab samples collected for SARS‐CoV‐2 testing. Among 295 SARS‐CoV‐2 infected patients, 92 returned home, 160 were admitted to medical wards, and 43 to the intensive care unit (ICU). Elevated TTV loads were observed in ICU patients (median: 3.02 log copies/mL, interquartile range [IQR]: 2.215–3.825), exceeding those in discharged (2.215, [0; 2.962]) or hospitalized patients (2.24, [0; 3.29]) (p = 0.006). Multivariate analysis identified diabetes, obesity, hepatitis, fever, dyspnea, oxygen requirement, and TTV load as predictors of ICU admission. A 2.91 log10 copies/mL TTV threshold independently predicted ICU admission. Nasopharyngeal TTV quantification in SARS‐CoV‐2 infected patients is linked to the likelihood of ICU admission and might reflect respiratory immunosuppression.